Monocrotaline

Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid. Monocrotaline inhibits OCT-1 and OCT-2 with IC50s of 36.8 µM and 1.8 mM, respectively. Monocrotaline has antitumor activity and is cytotoxic to hepatocellular carcinoma cells. Monocrotaline is used to induce a model of pulmonary hypertension in rodents. [2][6][8].

Product Specifications

CAS Number

[315-22-0]

Product Name Alternative

Crotaline

UNSPSC

12352005

Hazard Statement

H301, H351

Target

Others

Type

Natural Products

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Monocrotaline.html

Purity

99.96

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 2 mg/mL (ultrasonic)

Smiles

O=C(O[C@]1([H])CCN2[C@]1([H])C(CO3)=CC2)[C@H](C)[C@@](C)(O)[C@@](C)(O)C3=O

Molecular Formula

C16H23NO6

Molecular Weight

325.36

Precautions

H301, H351

References & Citations

[1]Gomez-Arroyo JG, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012 Feb 15;302 (4) :L363-9.|[2]Wu XH, et al. Experimental animal models of pulmonary hypertension: Development and challenges. Animal Model Exp Med. 2022 Sep; 5 (3) :207-216.|[3]Kusuma SS, et al. Antineoplastic activity of monocrotaline against hepatocellular carcinoma. Anticancer Agents Med Chem. 2014;14 (9) :1237-48.|[4]Jin H, et al. Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling. Int J Mol Med. 2021 Feb;47 (2) :595-606.|[5]Wilson DW, et, al. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol. 1992;22 (5-6) :307-25.|[6]Chen JY, et al. An in vitro study on interaction of anisodine and monocrotaline with organic cation transporters of the SLC22 and SLC47 families. Chin J Nat Med. 2019 Jul;17 (7) :490-497.|[7]Nogueira-Ferreira R, et al. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther. 2015 Dec;35:8-16.|[8]Zhao J, et al. Effects of paclitaxel intervention on pulmonary vascular remodeling in rats with pulmonary hypertension. Exp Ther Med. 2019 Feb;17 (2) :1163-1170.|[9]Rafikova O, et al. Metabolic Changes Precede the Development of Pulmonary Hypertension in the Monocrotaline Exposed RatLung. PLoS One. 2016 Mar 3;11 (3) :e0150480.|[10]Dumitrascu R, Kulcke C, Königshoff M, Kouri F, Yang X, Morrell N, Ghofrani HA, Weissmann N, Reiter R, Seeger W, Grimminger F, Eickelberg O, Schermuly RT, Pullamsetti SS. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J. 2011 May;37 (5) :1104-18.|[11]Aliotta JM, Pereira M, Wen S, Dooner MS, Del Tatto M, Papa E, Goldberg LR, Baird GL, Ventetuolo CE, Quesenberry PJ, Klinger JR. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice. Cardiovasc Res. 2016 Jun 1;110 (3) :319-30.